Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UNITED THERAPEUTICS (UTHR) Cash & Current Investments: 2009-2024

Historic Cash & Current Investments for UNITED THERAPEUTICS (UTHR) over the last 16 years, with Dec 2024 value amounting to $3.3 billion.

  • UNITED THERAPEUTICS's Cash & Current Investments fell 16.80% to $2.8 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $12.4 billion, marking a year-over-year increase of 3.37%. This contributed to the annual value of $3.3 billion for FY2024, which is 9.11% up from last year.
  • Per UNITED THERAPEUTICS's latest filing, its Cash & Current Investments stood at $3.3 billion for FY2024, which was up 9.11% from $3.0 billion recorded in FY2023.
  • In the past 5 years, UNITED THERAPEUTICS's Cash & Current Investments registered a high of $3.3 billion during FY2024, and its lowest value of $1.8 billion during FY2020.
  • Over the past 3 years, UNITED THERAPEUTICS's median Cash & Current Investments value was $3.0 billion (recorded in 2023), while the average stood at $3.0 billion.
  • Data for UNITED THERAPEUTICS's Cash & Current Investments shows a peak YoY skyrocketed of 47.03% (in 2022) over the last 5 years.
  • UNITED THERAPEUTICS's Cash & Current Investments (Yearly) stood at $1.8 billion in 2020, then climbed by 5.22% to $1.9 billion in 2021, then soared by 47.03% to $2.8 billion in 2022, then rose by 5.47% to $3.0 billion in 2023, then grew by 9.11% to $3.3 billion in 2024.